• 1.

    Mustafa R, et al. Clinical trials in nephrology: An updated systematic review of ClinicalTrials.gov. Kidney Week 2019; FR-PO1199. https://www.asn-online.org/education/kidneyweek/2019/program-abstract.aspx?controlId=3237149

    • Search Google Scholar
    • Export Citation
  • 2.

    Levin A, et al. Global kidney health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet 2017; 390:18881917. doi: 10.1016/S0140-6736(17)30788-2

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Evangelidis N, et al. Developing a set of core outcomes for trials in hemodialysis: An international Delphi survey. Am J Kidney Dis 2017; 70:464475. doi: 10.1053/j.ajkd.2016.11.029

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Flythe JE, et al. Cultivating a research-ready dialysis community. J Am Soc Nephrol 2019; 30:375380. doi: 10.1681/ASN.2018101059

  • 5.

    Thompson A, et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 2015; 26:29302937. doi: 10.1681/ASN.2015010091

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Allon M, et al. Recommended clinical trial end points for dialysis catheters. Clin J Am Soc Nephrol 2018; 13:495500. doi: 10.2215/CJN.12011116

  • 7.

    Smith KA, et al. Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 2019; 73:533541. doi: 10.1053/j.ajkd.2018.11.001

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Levey AS, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis 2020; 75:84104. doi: 10.1053/j.ajkd.2019.06.009

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Levey AS, et al. GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64:P821P835. doi: 10.1053/j.ajkd.2014.07.030

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Beathard GA, et al. Definitions and end points for interventional studies for arteriovenous dialysis access. Clin J Am Soc Nephrol 2018; 13:501512. doi: 10.2215/CJN.11531116

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Mackay M, et al. Establishing surrogate kidney end points for lupus nephritis clinical trials: Development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol 2019; 71:411419. doi: 10.1002/art.40724

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Thompson A, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 2019; 14:469481. doi: 10.2215/CJN.08600718

    • Crossref
    • Search Google Scholar
    • Export Citation

Patients as Partners in Clinical Trial Development—What Are We Waiting For?

Barbara S. GillespieBarbara S. Gillespie, MD, FASN, is vice president, Therapeutic Head of Nephrology, Covance, and adjunct professor, Division of Nephrology and Hypertension, University of North Carolina.

Search for other papers by Barbara S. Gillespie in
Current site
Google Scholar
PubMed
Close
Restricted access
Save